We finally evaluated the SOD2 activity, and the results showed that offspring in the maternal diabetes (STZ/VEH) group showed decreased SOD2 activity (P < 0.0001) compared to the CTL/VEH group; again, STZ/MnTBAP treatment completely, while RORA agonist (STZ/SR1078) partly (P < 0.01), reversed this effect (see Fig. 4f). This evidence concerns the gene RORA and diabetes mellitus.